Entrada Therapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

TRDA$5.25+11.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2026	2025	2026	2025
Collaboration revenue	$905	$1,614	$2,678	$24,122
Operating expenses:
Research and development	32,369	38,361	100,792	108,312
General and administrative	10,225	10,304	30,841	31,500
Total operating expenses	42,594	48,665	131,633	139,812
Loss from operations	(41,689)	(47,051)	(128,955)	(115,690)
Other income:
Interest and other income	1,974	3,571	6,833	11,936
Total other income	1,974	3,571	6,833	11,936
Loss before provision for income taxes	(39,715)	(43,480)	(122,122)	(103,754)
Provision for income taxes	27	654	100	832
Net loss	$(39,742)	$(44,134)	$(122,222)	$(104,586)
Net loss per share, basic and diluted	$(0.94)	$(1.06)	$(2.90)	$(2.53)
Weighted‑average common shares outstanding, basic and diluted	42,373,345	41,462,567	42,145,729	41,293,108
Other comprehensive (loss) gain
Unrealized (loss) gain on marketable securities	(122)	221	(708)	664
Total other comprehensive (loss) gain	(122)	221	(708)	664
Total comprehensive loss	$(39,864)	$(43,913)	$(122,930)	$(103,922)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.